PVLA Other | Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. Other

Cover page items of the 10-K and 10-Q that have no other home: a security other than the listed stock or a bond, a check box that differs from the latest cover, or a figure not in the Balance Sheet › Equity tabs. Newest first, as filed.

2026-03-31: Form 10-K; Item Stock registered under Section 12(b); As filed Common Stock, par value $0.001 per share · PVLA · NASDAQ.
2025-03-31: Form 10-K; Item Stock registered under Section 12(b); As filed Common Stock, par value $0.001 per share · PVLA · NASDAQ.
2024-11-13: Form 10-Q; Item Stock registered under Section 12(b); As filed Common Stock, $0.001 par value per share · PIRS · NASDAQ.
2024-08-14: Form 10-Q; Item Stock registered under Section 12(b); As filed Common Stock, $0.001 par value per share · PIRS · NASDAQ.

Filed	Form	Item	As filed
2026-03-31	10-K	Stock registered under Section 12(b)	Common Stock, par value $0.001 per share · PVLA · NASDAQ
2025-03-31	10-K	Stock registered under Section 12(b)	Common Stock, par value $0.001 per share · PVLA · NASDAQ
2024-11-13	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2024-08-14	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2024-05-15	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2024-04-29	10-K/A	Stock registered under Section 12(b)	Common Stock · PIRS · NASDAQ
2024-03-29	10-K	Stock registered under Section 12(b)	Common Stock, par value $0.001 per share · PIRS · NASDAQ
2023-11-14	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2023-08-10	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2023-05-11	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2023-03-31	10-K	Stock registered under Section 12(b)	Common Stock, par value $0.001 per share · PIRS · NASDAQ
2022-11-04	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2022-08-04	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2022-07-06	10-K/A	Stock registered under Section 12(b)	Common Stock, par value $0.001 per share · PIRS · NASDAQ
2022-05-11	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2022-03-02	10-K	Stock registered under Section 12(b)	Common Stock, par value $0.001 per share · PIRS · NASDAQ
2021-11-02	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2021-08-05	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2021-05-17	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2021-03-31	10-K	Stock registered under Section 12(b)	Common Stock, par value $0.001 per share · PIRS · NASDAQ
2020-11-04	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2020-08-10	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2020-05-11	10-Q	Stock registered under Section 12(b)	Common Stock, $0.001 par value per share · PIRS · NASDAQ
2020-03-13	10-K	Stock registered under Section 12(b)	Common Stock, par value $0.001 per share · PIRS · NASDAQ
2019-11-12	10-Q	Emerging growth company	Yes
2019-08-09	10-Q	Emerging growth company	Yes
2019-05-10	10-Q	Emerging growth company	Yes
2015-03-30	10-K	Voluntary filer	Yes
2014-11-13	10-Q	Voluntary filer	Yes
2014-09-12	10-K	Voluntary filer	Yes
2014-06-02	10-Q	Voluntary filer	Yes
2014-05-14	10-Q	Voluntary filer	Yes

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Braveheart Bio, Inc. (BRVE)	United States	$2.106B
Bausch Health Companies Inc. (BHC)		$2.113B	-1.68
Trevi Therapeutics, Inc. (TRVI)	United States	$2.091B	-51.93
Generate Biomedicines, Inc. (GENB)	United States	$2.052B
OCULAR THERAPEUTIX, INC (OCUL)	United States	$2.159B	-7.15
Prestige Consumer Healthcare Inc. (PBH)	United States	$2.163B	13.03
PERRIGO Co plc (PRGO)	Ireland	$2.038B	-0.79
NEKTAR THERAPEUTICS (NKTR)	United States	$2.026B	-9.05
UroGen Pharma Ltd. (URGN)		$2.015B	-18.42
Nuvation Bio Inc. (NUVB)	United States	$2.007B	-13.12